← Eichor
Study identifier: NCT07045571 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

MSCAN: ctDNA Methylation as Prognostic and Theranostic Tool for Pancreatic Cancer

Condition: Pancreatic Neoplasm · Pancreas Cancer  ·  Sponsor: Yingbin Liu, MD, PhD, FACS

PhaseN/A
Planned participants1000
Who can joinAll sexes, N/A to no upper limit
Healthy volunteersNo

About this study

Developing a characteristic ctDNA methylation panel for pancreatic ductal adenocarcinoma and establishing an intelligent diagnostic and dynamic monitoring model based on ctDNA methylation.

This description comes directly from the study's public registry record.

Talk to the study team

Yinbin Liu, PhD  ·  +86 13918803900  ·  laoniulyb@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

Renji hospital, Shanghai Jiaotong University School of MedicineShanghai, Shanghai Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07045571